Accessibility Menu
Lipella Pharmaceuticals logo

Lipella Pharmaceuticals(OTC) LIPO

Market Cap$151.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-96%
1 Month-59%
$0.03
-49.38%
-0.03Today
Lipella Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.032026-07-21
Lipella Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-52.66%USD 0.072026-07-14
1 month-59.13%USD 0.082026-06-18
3 month+61.08%USD 0.022026-04-22
Year to date-81.83%USD 0.182025-12-31
1 year-95.91%USD 0.802025-07-21
3 year-99.8%USD 16.402023-07-21
Since inception-99.91%USD 37.682022-12-20

Lipella Pharmaceuticals Financials at a Glance

Market Cap

$151.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$173.67K

Net Income (TTM)

-$5.33M

EPS (TTM)

-$2.41

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

0.40 (Low)

Price

$0.03

Volume

3

Open

$0.06

Previous Close

$0.03

Daily Range

$0.03 - $0.06

52-Week Range

$0.02 - $0.78

Estimated Earnings Date

Jun 3, 2026

LIPO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lipella Pharmaceuticals

Lipella develops new drug treatments for hard-to-treat diseases. Its main products help people with bladder and mouth conditions. The company reformulates existing drugs to target unmet medical needs.

What’s in the Medicine Cabinet?

  • LP-10 (Bladder Health): Reformulated tacrolimus for radiation-induced bladder bleeding; targets patients with no approved therapies. (100% of revenue from grants, not product sales)
  • LP-310 (Oral Health): Oral tacrolimus for oral lichen planus, a chronic mouth condition; in clinical trials.
  • LP-410 (Rare Disease): Liposomal tacrolimus for oral graft-versus-host disease, a complication after stem cell transplants; advancing toward clinical development.
  • LP-50 (Cancer Research): Immunoglobulin-based therapy for early-stage bladder cancer; preclinical development.
  • Drug Delivery Platform: Proprietary liposome system for targeted delivery to tissues like the bladder and mouth.

Growth Spurts and Growing Pains

  • Launched Phase IIa trial for LP-10 in 2024; ongoing in 2025.
  • Started multi-center Phase 2a trial for LP-310 in 2024; expected to finish in Q3 2025.
  • Received FDA investigational new drug approval to begin trials for LP-410 in 2024; received orphan drug status in 2023.
  • Renewed headquarters lease for five years in July 2025.
  • No acquisitions or global market entries reported as of June 2025.

Why Lipella Stands Out (Without the Hype)

Lipella focuses on reformulating existing drugs for new uses, aiming to lower development risks and costs. Its proprietary liposome delivery system targets drugs directly to affected tissues, reducing side effects. The company holds patents in the US, Australia, Canada, and Europe, supporting its approach to rare and underserved diseases.

Five Things You Need to Know

  • Revenue was $87,000 in Q2 2025, compared to $136,431 in Q2 2024.
  • All revenue comes from US government grants, not product sales.
  • Net loss was $1.33 million in Q2 2025, a 41.5% increase in loss compared to Q2 2024.
  • Cash and equivalents were $2.78 million as of June 30, 2025.
  • Delisted from Nasdaq in June 2025; now trades on OTC Markets.

Bottom Line

Lipella is a small biotech focused on reformulating drugs for rare diseases. The company relies on grants and faces ongoing financial challenges as it advances clinical trials.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7

CEO

Jonathan Kaufman, PhD, MBA

Website

www.lipella.com

Headquarters

Pittsburgh, PA 15208, US

LIPO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-140.39%

Return on Capital

-258.28%

Return on Assets

-165.46%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$151.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.62M

Volume

3

Avg. Volume

38.78K

Financials (TTM)

Gross Profit

-$3.39M

Operating Income

-$5.41M

EBITDA

-$5.33M

Operating Cash Flow

-$2.36B

Capital Expenditure

$0.00

Free Cash Flow

-$2.36B

Cash & ST Invst.

$1.86M

Total Debt

$264.08K

Lipella Pharmaceuticals Performance Analysis

Lipella Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 259,347N/A
20222022-12-31USD 184,156-29.0%
20232023-12-31USD 449,617144.2%
20242024-12-31USD 536,35719.3%
Lipella Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31-100.0%
Q22025-06-30N/A
Q32025-09-30N/A
Lipella Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -2.60N/A
20222022-12-31USD -3.6239.3%
20232023-12-31USD -6.1670.1%
20242024-12-31USD -4.79-22.3%
Lipella Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-6.2%
Q12025-03-3153.3%
Q22025-06-3051.6%
Q32025-09-309.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$720.97K

+31.1%

Gross Margin

0.00%

N/A

Market Cap

$151.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$21.59K

N/A

Employees

7

N/A

Net Income

-$1.25M

+13.2%

EBITDA

-$1.25M

+13.2%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$1.86M

+37.1%

Total Debt

$264.08K

+272.8%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$219.82K

N/A

Short Term Debt

$44.27K

-37.5%

Return on Assets

-1.65%

N/A

Return on Invested Capital

-2.32%

N/A

Free Cash Flow

-$2.36B

-360909.2%

Operating Cash Flow

-$2.36B

-360909.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PBMPsyence Biomedical Ltd.
$3.04+3.05%
PTIXProtagenic Therapeutics, Inc.
$0.22-24.34%
VRAXVirax Biolabs Group Limited
$3.10-2.82%
DRMADermata Therapeutics, Inc.
$1.29-2.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About LIPO

What is the current price of Lipella Pharmaceuticals?

Lipella Pharmaceuticals is trading at $0.03 per share.

What is the 52-week range for Lipella Pharmaceuticals?

Over the past 52 weeks, Lipella Pharmaceuticals has traded between $0.02 and $0.78.

How much debt does Lipella Pharmaceuticals have?

As of the most recent reporting period, Lipella Pharmaceuticals reported total debt of $264.08K.

How much cash does Lipella Pharmaceuticals have on hand?

Lipella Pharmaceuticals reported $1.86M in cash and cash equivalents in its most recent financial results.

What is Lipella Pharmaceuticals’s dividend yield?

Lipella Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services